Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients: Subgroup analysis of the cilostazol stroke prevention study

Cerebrovascular Diseases

Volumn 26, Issue 1, 2008, Pages 63-70

  Shinohara, Yukito ^a   Gotoh, Fumio ^b   Tohgi, Hideo ^f   Hirai, Shunsaku ^g   Terashi, Akiro ^c   Fukuuchi, Yasuo ^h   Otomo, Eiichi ^d   Itoh, Eiichi ⁱ   Matsuda, Tamotsu ^j   Sawada, Tohru ^k   Yamaguchi, Takenori ^l   Nishimaru, Katsuya ^m   Ohashi, Yasuo ^e  

^a Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d Department of Internal Medicine

^e UNIVERSITY OF TOKYO   (Japan)

^f IWATE MEDICAL UNIVERSITY   (Japan)

^g GUNMA UNIVERSITY   (Japan)

^h ASHIKAGA RED CROSS HOSPITAL   (Japan)

ⁱ Meito ku   (Japan)

^j KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^k Aino Hospital

^l NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^m Yoshizuka Hayashi Hospital   (Japan)

more..

Author keywords

Antiplatelet; Diabetes; Hypertension; Lacunar infarction; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUDILAST; IFENPRODIL TARTRATE; NICERGOLINE; PLACEBO;

ARTICLE; BLEEDING; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; SECONDARY PREVENTION; STROKE;

AGED; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 46449099089     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135654     Document Type: Article

References (29)

1. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Masuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147-157.
3. Shinohara Y, for the CSPS group: Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 2006;22:57-60.
4. Kohda N, Tani T, Nakayama S, Adachi T, Marukawa K, Ito R, Ishida K, Matsumoto Y, Kimura Y: Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999;96:261-268.
5. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamawaki T, Itoh N, Obara K, Muramatsu K: Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989;20:668-673.
6. Kim KY, Shin HK, Choi JM, Hong KW: Inhibition of lipopolysaccharide- induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002;300:709-715.
7. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y: Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000;152:299-305.
8. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
9. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, the MOSES Study Group: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1224.
10. Xu G, Liu X, Wu W, Zhang R, Yin Q: Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovasc Dis 2007;23:117-120.
11. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K: Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA 1987;257:949-952.
12. Barrett-Connor E, Khaw KT: Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 1988;128:116-123.
13. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
14. Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K: Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994;25:951-957.
15. Lai SM, Alter M, Friday G, Sobel E: A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994;25:958-962.
16. Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser MG, Colman SA, Woodward M, on behalf of the PROGRESS Collaborative Group: Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004;13:7-13.
17. Rothwell PM: Prevention of stroke in patients with diabetes mellitus and the metabolic syndrome. Cerebrovasc Dis 2005;20:24-34.
18. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
19. Alter M, Lai SM, Friday G, Singh V, Kumar VM, Sobel E: Stroke recurrence in diabetics. Stroke 1997;28:1153-1157.
20. Ariesen MJ, Algra A, Kappelle LJ: Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006;37:134-138.
21. Kimura Y, Tani T, Kanbe T, Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-1149.
22. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H: Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000;59:347-356.
23. Lindenstrom E, Boysen G, Nyboe J: Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994;309:11-15.
24. Tanne D, Yaari S, Goldbourt U: High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8,586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-87.
25. Simons LA, McCallum J, Friedlander Y, Simons J: Risk factors for ischemic stroke: Dubbo Study of the elderly. Stroke 1998;29:1341-1346.
26. Shimizu M, Yamamoto M, Ando Y, Tabata O, Shinohara Y: Detection of activated platelets in patients with cerebral infarction at the acute and chronic stages. Jpn J Stroke 2002;24:234-239.
27. American Diabetes Association: Aspirin therapy in diabetes. Diabetes Care 2004;27(suppl 1):S72-S73.
28. Collaborative Group of the Primary Prevention Project (PPP): Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
29. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, on behalf of the PPP Collaborative Group: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-3272.